Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters








Database
Language
Publication year range
1.
Br J Cancer ; 110(6): 1622-33, 2014 Mar 18.
Article in English | MEDLINE | ID: mdl-24548857

ABSTRACT

BACKGROUND: Proteomics-based approaches for biomarker discovery are promising strategies used in cancer research. We present state-of-art label-free quantitative proteomics method to assess proteome of renal cell carcinoma (RCC) compared with noncancer renal tissues. METHODS: Fresh frozen tissue samples from eight primary RCC lesions and autologous adjacent normal renal tissues were obtained from surgically resected tumour-bearing kidneys. Proteins were extracted by complete solubilisation of tissues using filter-aided sample preparation (FASP) method. Trypsin digested proteins were analysed using quantitative label-free proteomics approach followed by data interpretation and pathways analysis. RESULTS: A total of 1761 proteins were identified and quantified with high confidence (MASCOT ion score threshold of 35 and P-value <0.05). Of these, 596 proteins were identified as differentially expressed between cancer and noncancer tissues. Two upregulated proteins in tumour samples (adipose differentiation-related protein and Coronin 1A) were further validated by immunohistochemistry. Pathway analysis using IPA, KOBAS 2.0, DAVID functional annotation and FLink tools showed enrichment of many cancer-related biological processes and pathways such as oxidative phosphorylation, glycolysis and amino acid synthetic pathways. CONCLUSIONS: Our study identified a number of differentially expressed proteins and pathways using label-free proteomics approach in RCC compared with normal tissue samples. Two proteins validated in this study are the focus of on-going research in a large cohort of patients.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Renal Cell/chemistry , Kidney Neoplasms/chemistry , Proteomics/methods , Aged , Aged, 80 and over , Biomarkers, Tumor/biosynthesis , Biomarkers, Tumor/urine , Carcinoma, Renal Cell/metabolism , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/urine , Female , Humans , Kidney Neoplasms/metabolism , Kidney Neoplasms/pathology , Kidney Neoplasms/urine , Male , Mass Spectrometry , Middle Aged , Neoplasm Proteins/analysis , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/urine , Signal Transduction
2.
Oncogene ; 32(29): 3461-9, 2013 Jul 18.
Article in English | MEDLINE | ID: mdl-22986526

ABSTRACT

The RNA helicase p68 (DDX5) is an established co-activator of the p53 tumour suppressor that itself has a pivotal role in orchestrating the cellular response to DNA damage. Although several factors influence the biological outcome of p53 activation, the mechanisms governing the choice between cell-cycle arrest and apoptosis remain to be elucidated. In the present study, we show that, while p68 is critical for p53-mediated transactivation of the cell-cycle arrest gene p21(WAF1/CIP1), it is dispensable for induction of several pro-apoptotic genes in response to DNA damage. Moreover, p68 depletion results in a striking inhibition of recruitment of p53 and RNA Pol II to the p21 promoter but not to the Bax or PUMA promoters, providing an explanation for the selective effect on p21 induction. Importantly, these findings are mirrored in a novel inducible p68 knockout mouse model in which p68 depletion results in a selective inhibition of p21 induction in several tissues. Moreover, in the bone marrow, p68 depletion results in an increased sensitivity to γ-irradiation, consistent with an increased level of apoptosis. These data highlight a novel function of p68 as a modulator of the decision between p53-mediated growth arrest and apoptosis in vitro and in vivo.


Subject(s)
Apoptosis/physiology , Cell Cycle Checkpoints/physiology , Cyclin-Dependent Kinase Inhibitor p21/biosynthesis , DEAD-box RNA Helicases/metabolism , DNA Damage/physiology , Animals , Blotting, Western , Chromatin Immunoprecipitation , Flow Cytometry , Immunohistochemistry , Mice , Mice, Knockout , Real-Time Polymerase Chain Reaction , Signal Transduction/physiology , Transcriptional Activation/physiology , Transfection , Tumor Suppressor Protein p53/metabolism
3.
Br J Cancer ; 106(6): 1117-22, 2012 Mar 13.
Article in English | MEDLINE | ID: mdl-22361631

ABSTRACT

BACKGROUND: Observations that diabetics treated with biguanide drugs have a reduced risk of developing cancer have prompted an enthusiasm for these agents as anti-cancer therapies. We sought to determine the efficacy of the biguanide phenformin in the chemoprophylaxis and in the treatment of oestrogen receptor (ER)-positive MCF7 and receptor triple-negative MDAMB231 xenografts in immunocompromised mice. We also compared the efficacy of phenformin and metformin in the treatment of MDAMB231. METHODS: Immunocompromised mice were divided into groups: (1) phenformin administered for 2 weeks prior to cell injection; (2) established tumours treated with phenformin; (3) established tumours treated with metformin (only for MDAMB231 tumours); (4) untreated controls. Post-treatment tumours, liver and spleen were harvested for further analysis. RESULTS: Phenformin significantly inhibited both the development and growth of MCF7 and MDAMB231 tumours, and for MDAMB231 at greater efficacy than metformin without murine toxicity. The number of mitotic figures was significantly fewer in xenografts treated with phenformin compared with controls. Results suggested that the mechanism of action of phenformin in vivo is consistent with AMPK activation. CONCLUSION: Phenformin has clinical potential as an antineoplastic agent and should be considered for clinical trials both in ER-positive and triple-negative breast cancer.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Antineoplastic Agents/therapeutic use , Breast Neoplasms/prevention & control , Metformin/therapeutic use , Phenformin/therapeutic use , Adenylate Kinase/metabolism , Animals , Anticarcinogenic Agents/pharmacology , Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Line, Tumor , Enzyme Activation , Female , Histones/metabolism , Humans , Ki-67 Antigen/metabolism , Liver/enzymology , Metformin/pharmacology , Mice , Mice, Nude , Phenformin/pharmacology , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/metabolism , Spleen/enzymology , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
4.
Oncogene ; 29(49): 6475-84, 2010 Dec 09.
Article in English | MEDLINE | ID: mdl-20818423

ABSTRACT

The RNA helicase p68 is a potent co-activator of p53-dependent transcription in response to DNA damage. Previous independent studies have indicated that p68 and the Δ133p53 isoforms, which modulate the function of full-length p53, are aberrantly expressed in breast cancers. Here we identify a striking inverse association of p68 and Δ133p53 expression in primary breast cancers. Consistent with these findings, small interfering RNA depletion of p68 in cell lines results in a p53-dependant increase of Δ133p53 in response to DNA damage, suggesting that increased Δ133p53 expression could result from downregulation of p68 and provide a potential mechanistic explanation for our observations in breast cancer. Δ133p53α, which has been shown to negatively regulate the function of full-length p53, reciprocally inhibits the ability of p68 to stimulate p53-dependent transcription from the p21 promoter, suggesting that Δ133p53α may be competing with p68 to regulate p53 function. This hypothesis is underscored by our observations that p68 interacts with the C-terminal domain of p53, co-immunoprecipitates 133p53α from cell extracts and interacts only with p53 molecules that are able to form tetramers. These data suggest that p68, p53 and 133p53α may form part of a complex feedback mechanism to regulate the expression of Δ133p53, with consequent modification of p53-mediated transcription, and may modulate the function of p53 in breast and other cancers that harbour wild-type p53.


Subject(s)
Breast Neoplasms/metabolism , DEAD-box RNA Helicases/metabolism , Tumor Suppressor Protein p53/metabolism , Breast Neoplasms/pathology , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Female , Gene Expression Regulation, Neoplastic , Humans , Promoter Regions, Genetic , Protein Interaction Domains and Motifs , Protein Isoforms/metabolism , RNA, Small Interfering/metabolism
5.
Oncogene ; 28(46): 4053-64, 2009 Nov 19.
Article in English | MEDLINE | ID: mdl-19718048

ABSTRACT

The DEAD-box RNA helicases p68 (DDX5) and p72 (DDX17) have been shown to act as transcriptional co-activators for a diverse range of transcription factors, including oestrogen receptor-alpha (ERalpha). Here, we show that, although both proteins interact with and co-activate ERalpha in reporter gene assays, small interfering RNA-mediated knockdown of p72, but not p68, results in a significant inhibition of oestrogen-dependent transcription of endogenous ERalpha-responsive genes and oestrogen-dependent growth of MCF-7 and ZR75-1 breast cancer cells. Furthermore, immunohistochemical staining of ERalpha-positive primary breast cancers for p68 and p72 indicate that p72 expression is associated with an increased period of relapse-free and overall survival (P=0.006 and 0.016, respectively), as well as being inversely associated with Her2 expression (P=0.008). Conversely, p68 shows no association with relapse-free period, or overall survival, but it is associated with an increased expression of Her2 (P=0.001), AIB-1 (P<0.001) and higher tumour grade (P=0.044). Our data thus highlight a crucial role for p72 in ERalpha co-activation and oestrogen-dependent cell growth and provide evidence in support of distinct but important roles for both p68 and p72 in regulating ERalpha activity in breast cancer.


Subject(s)
Breast Neoplasms/pathology , Cell Proliferation , DEAD-box RNA Helicases/physiology , Estrogen Receptor alpha/physiology , Estrogens/pharmacology , Transcription, Genetic , Animals , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , COS Cells , Cell Proliferation/drug effects , Cell Survival/drug effects , Cell Survival/genetics , Chlorocebus aethiops , DEAD-box RNA Helicases/metabolism , Estrogen Receptor alpha/genetics , Estrogen Receptor alpha/metabolism , Estrogens/metabolism , Female , Gene Expression Regulation, Neoplastic , Humans , Nuclear Receptor Coactivator 1/metabolism , Nuclear Receptor Coactivator 1/physiology , Protein Binding , Transcription, Genetic/drug effects , Transcription, Genetic/genetics , Transcriptional Activation , Tumor Cells, Cultured
6.
J Pathol ; 190(1): 39-46, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10640990

ABSTRACT

We are exposed constantly to potentially harmful compounds and radiations. Complex adaptive protective responses have evolved to prevent such agents causing cellular damage, including potentially oncogenic mutation. The p53 tumour suppressor appears to have a role in co-ordinating such responses: it is activated by diverse insults and it acts as a transcriptional regulator of downstream genes that facilitate cellular adaptation. Ultraviolet (UV) light is a particularly potent inducer of p53 expression. In addition, UV light induces the production of melanin as a protection against further irradiation-induced damage. This study shows that the promoters of the genes coding for the enzymes crucial in melanin biosynthesis, namely tyrosinase and tyrosinase-related protein-1 (TRP-1), are activated by wild-type p53. Both promoters have p53-responsive elements and are activated in vivo in a dose-dependent manner by wild-type p53, as well as by the p53 homologues p73alpha and p63alpha.


Subject(s)
Melanins/biosynthesis , Membrane Glycoproteins , Monophenol Monooxygenase/genetics , Oxidoreductases , Promoter Regions, Genetic/genetics , Proteins/genetics , Skin/radiation effects , Tumor Suppressor Protein p53/metabolism , Ultraviolet Rays , Base Sequence , Binding Sites , Enzyme Activation/genetics , Gene Expression Regulation/radiation effects , Humans , Molecular Sequence Data , Monophenol Monooxygenase/metabolism , Polymerase Chain Reaction , Skin/metabolism , Transcription, Genetic , Tumor Cells, Cultured
7.
Stem Cells ; 16(4): 248-60, 1998.
Article in English | MEDLINE | ID: mdl-9708447

ABSTRACT

Abnormalities of the p53 tumor suppressor gene are the single most common molecular abnormality seen in human cancer. Considerable evidence indicates that the product of this gene has critical roles in coordinating the response of cells to a diverse range of environmental stresses. At present, there is a gamut of biochemical properties and interactions ascribed to p53, but the in vivo physiological relevance of many of these remains uncertain. The development of clinical applications and novel therapeutic strategies utilizing our knowledge of p53 is contingent upon bridging the gap between rigorous biochemistry and holistic in vivo studies.


Subject(s)
Tumor Suppressor Protein p53 , Animals , Humans , Structure-Activity Relationship , Tumor Suppressor Protein p53/chemistry , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Protein p53/physiology
SELECTION OF CITATIONS
SEARCH DETAIL